RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive: Partial deletions of RUNX1 and PMRD16, expression of RUNX1/PMRD16, and mutations in GATA2 activation are also associated with CML progression and their presence may be detected in CML14, 35.